Revista Digital Universitaria
Revista Digital Universitaria ISSN: 1607 - 6079 | Publicación mensual | 1 de junio de 2014 vol.15, No.06


Genomic of metabolic diseases

Lorena Orozco, Angélica Graciela Martínez, Francisco Martín Barajas Olmos

Metabolic diseases are a major public health and Mexico is one of the countries with the highest prevalence. Recently, have been identified several polymorphisms associated with risk for developing metabolic disorders. Knowledge of the genetic basis of the disease is improving due to technological advances and the ability to raise large collections of patients. It is possible that soon a "metabolic disorders risk" prognostic algorithm will include genetic markers for patient stratification, prediction of disease manifestations and definition of targeted therapy. Currently are being identified polymorphisms that are much more common in individuals with Native American ancestry than in other populations, such as R230C variant in the ABCA1 gene and a haplotype in the SLC16A11 gene, strongly associated with low levels of HDL cholesterol, obesity, and type 2 diabetes. Personalized medicine will continue to improve as the list of number of markers and identification of gene-gene and gene-environment interactions increase. It is clear the urgent need to understand how these polymorphisms change the molecular and cell biology of the metabolism pathways that predispose to the development of the different metabolic diseases..

Keywords: Metabolic diseases, metabolic syndrome, obesity, diabetes, hypertension, polymorphism, genomic.